BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I. The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma? Cancers (Basel) 2021;13:3248. [PMID: 34209646 DOI: 10.3390/cancers13133248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Guo Y, Ren Y, Dong X, Kan X, Zheng C. An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation. JHC 2022;Volume 9:343-55. [DOI: 10.2147/jhc.s358539] [Reference Citation Analysis]
2 Herranz-Itúrbide M, Peñuelas-Haro I, Espinosa-Sotelo R, Bertran E, Fabregat I. The TGF-β/NADPH Oxidases Axis in the Regulation of Liver Cell Biology in Health and Disease. Cells 2021;10:2312. [PMID: 34571961 DOI: 10.3390/cells10092312] [Reference Citation Analysis]
3 Bao X, Liu Y, Huang J, Yin S, Sheng H, Han X, Chen Q, Wang T, Chen S, Qiu Y, Zhang C, Yu H. Stachydrine hydrochloride inhibits hepatocellular carcinoma progression via LIF/AMPK axis. Phytomedicine 2022;100:154066. [PMID: 35366490 DOI: 10.1016/j.phymed.2022.154066] [Reference Citation Analysis]
4 Srivastava A, Sharma H, Khanna S, Sadhu Balasundaram T, Chowdhury S, Chowdhury R, Mukherjee S. Interleukin-6 Induced Proliferation Is Attenuated by Transforming Growth Factor-β-Induced Signaling in Human Hepatocellular Carcinoma Cells. Front Oncol 2022;11:811941. [DOI: 10.3389/fonc.2021.811941] [Reference Citation Analysis]
5 Akce M, El-rayes BF, Bekaii-saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update. Therap Adv Gastroenterol 2022;15:175628482210861. [DOI: 10.1177/17562848221086126] [Reference Citation Analysis]